A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled study will assess the safety, tolerability,
and pharmacokinetics of single and multiple orally administered doses of EDP-305 in healthy
adult subjects, and adult subjects with presumptive NAFLD (i.e., obese subjects with or
without prediabetes or T2DM).